

# The Effect of Dopamine D2 Receptor TAQ A1 Allele on Sprinter and Endurance Athlete

Öznur Özge Özcan, Canan Sercan, Hamza Kulaksız, Mesut Karahan, Korkut Ulucan

**Abstract**—Genetic structure is very important to understand the brain dopamine system which is related to athletic performance. Hopefully, there will be enough studies about athletics performance in the terms of addiction-related genetic markers in the future. In the present study, we intended to investigate the Receptor-2 Gene (*DRD2*) rs1800497, which is related to brain dopaminergic system. 10 sprinter and 10 endurance athletes were enrolled in the study. Real-Time Polymerase Chain Reaction method was used for genotyping. According to results, A1A1, A1A2 and A2A2 genotypes in athletes were 0 (%0), 3 (%15) and 17 (%85). A1A1 genotype was not found and A2 allele was counted as the dominating allele in our cohort. These findings show that dopaminergic mechanism effects on sport genetic may be explained by the polygenic and multifactorial view.

**Keywords**—Addiction, athletic performance, genotype, polymorphism, sport genetics.

## I. INTRODUCTION

ATHLETIC performance is a significant part of the athletes and genetic factors contributing to athletic performance without doubt [1], [2]. Genotyping provides us to obtain information about genomic research, including sports medicine and exercise science and also muscle strength, cardiopulmonary capacity, body weight, adiposity, insulin and glucose metabolism [3]. Additional components of athletic performance include physical and mental factors with the combination of genetic variants [4]. Therefore, the question is not about performance-related features are heritable, but 'which' genetic variants remain substantial to athletic performance, and we are able to use these variants to identify future athletes [5].

Brachial slices were separated by Falck Hillarp method. By this method, monoamines are localized in the neuronal bodies of Substantia Nigra (SN) and Striatum with visualization of monoamines [6]. These regions are the medial hypothalamus branching through Ventral Tegmental Area (VTA), SN and the arcuate nucleus. There are four pathways that have been discovered as nigrostriatal, mesolimbic, mesocortical and tuberoinfundibular, which carry DA to other brain regions. The fifth, the thalamic pathway, is still researched by the scientists [7]. Dopamine (DA) has been identified a neurotransmitter of the dopaminergic system by the end of the 1950s [8]. DA is a neurotransmitter of Central Nervous System (CNS) and leads the motivation, motor control and reward system [9]. DA is a key to brain's processing and mesolimbic pathway, which extends from VTA to the striatum ventral, including amygdala,

hippocampus, and orbitofrontal cortex. Because it involves the limbic system, it has emotional, cognitive, and sensorimotor functions, and consequently pleasant feelings are associated in the control of reward and drug addiction [10]. The dopaminergic reward system plays a critical role in sex addiction, obesity, gambling as well as in neuropsychiatric disorders including schizophrenia, attention deficit hyperactivity disorder (ADHD) [11], [12]. During exercise, DA was shown to increase in the direction of release in the midbrain, hypothalamus and striatum [13]. Sensory perception and sensory-motor integration is more effective when DA is released by the physical activity [14]. Especially, anaerobic exercise like athleticism is important for the treatment of addiction, ADHD and neurodegenerative disorders like Parkinson Disease (PD) [15]-[18]. Physical exercise can also be a treatment for depression [19]. Physical exercise may protect people from depression disease [20].

The rs1800497 on chromosome 11q23.2 is located in exon 8 of the ankyrin repeat domain containing one gene downstream of *DRD2* [21]. Most of DA 2 receptors are intensively distributed on the postsynaptic, non-dopaminergic neurons in the striatum where D2 signaling modulates a variety of functional domains, including reward processing [22], [23]. In past years, numerous genetic association studies have focused on the single-nucleotide polymorphism (SNP) rs1800497 (also known as Taq1A).

In the present study, we aimed to analyze the distribution of *DRD2* rs1800497 polymorphism in sprinter and endurance athletes. This polymorphism is firstly related with addiction, and therefore we hypothesized that sports willingness and athletic performance is related with addiction mechanism.

## II. MATERIALS AND METHODS

### A. Subjects

10 sprinter and 10 endurance athletes were enrolled for the study. Üsküdar University Ethics Committee approved the study protocol, which was in accordance with the principles of the Declaration of Helsinki II. All subjects read, understood and confirmed the study by signing the informed consents explaining the study steps.

### B. DNA Sample Collection and Genotyping

DNA samples were collected by DNA collector swap and isolated with DNA purification kit (ThermoFisher Invitrogen),

Korkut Ulucan is an academician in Molecular Biology and Genetic Department, University of Uskudar, Altunizade Mahallesi, Haluk Turksöy Sk. No:14, 34662 Üsküdar/İstanbul/ Turkey (phone: +9021640022-2409; e-mail: korkut.ulucan@uskudar.edu.tr).

by following manufacturer's instructions. The rs1800497 genotyping was carried out by Real-Time Polymerase Chain Reaction (RT-PCR) by using commercially provided Taqman

Genotyping Assay (Catalog no: #4351379 Thermofisher, USA), by using specific primers (Table I).

TABLE I  
PRIMERS USED FOR THE GENOTYPING OF RS 1800497

DNA sequence (5'→3')	
<i>DRD2</i> (Exon 9)	5'-primer: 5'-CACAGCCATCCTCAAAGTGCTGGTC-3' (VIC)
	3'-primer: 5'-AGGCAGGCGCCAGCTGGACGTCCA'-3' (FAM)

### III. RESULTS

20 athletes participated in our study. 10 of those athletes were sprinter athletes, and the others were endurance athletes. 3 of the athletes (15%) had AG (A1A2) and 17 (85%) had GG (A2A2) Genotypes (Fig. 1). Primer used for the genotyping of

rs 1800497 is shown in Table I. We detected no A1A1 Genotypes in our cohort. (A) Allele was counted as 3 (7.5%) and (G) Allele as 37 (92.5%). Genotype and allele distributions of *DRD2* rs1800497 polymorphism in athletes are shown in Table II.




Fig. 1 Genotype results of the athletes

TABLE II  
GENOTYPES AND ALLELES

Alleles	Genotypes			Alleles	
	A <sub>1</sub> A <sub>1</sub>	A <sub>1</sub> A <sub>2</sub>	A <sub>2</sub> A <sub>2</sub>	A <sub>1</sub>	A <sub>2</sub>
Number of Athletes (%)	0	3	17	3	37
	% 0	% 15	% 85	% 7.5	% 92.5

### IV. DISCUSSION

The neurotransmitters of the CNS have many functional regulations such as learning, memory, motivation, reward and

behavior [24]. In addition to enhancing the activity of the CNS which also affects the physiological mechanisms in the brain, it is also effective in stress response and motor control generally also the levels of the brain are increasing in the CNS due to endurance exercise [25]-[27]. The detection of DA levels in the brain has provided us to examine addiction and diseases mechanism. There are different 5 types of DA receptors; D1, D2, D3, D4 and D5 [28]. One of these types of receptor is the D2 receptor. DA receptors show different distributions with respect to brain localization [29]. D1 receptor is quite abundant

in the striatum; D5 receptor is in hippocampus and the Entorhinal Cortex. The D2 receptor is observed in the striatum, hippocampus, amygdala and thalamus. D2 receptor is lower in the prefrontal cortex. D3 receptor, like other receptors, is in the striatum and considerable amount in the ventral striatum. D4 receptor is separated from the prefrontal cortex, found in the hippocampus, while the other is absent in the striatum [30]. The D2 receptor that has been proven to increase long-term release from the VTA that was cloned in 1988 [31] and other D1, D3, D4 and D5 receptors were later described.

There are two alleles of the rs1800497: A1 and A2 and Taq1A polymorphism is the most widely studied polymorphism in psychiatry [32]. In particular, genotyping based on allele distribution frequencies of genes involved in the secretion of monoamines as neurotransmitters; plays an important role in the analysis of SNP results of the susceptibility to psychiatric and neurological diseases such as schizophrenia, bipolar disorder and major depression [33], [34]. In recent years, focusing on behavior and nutritional demand, the desire to stimulate areas that seek to find taste in drug rewards such as drugs has led to various gene polymorphisms. Drug addiction has been associated with the association of the A1 allele of the DA D2 gene with cocaine, alcohol and opioid. Making such polymorphisms is important for solving the predisposition of the individual to addiction [35]-[37]. A1 Alleles carriers have a reduced number of receptor binders in the cellular membrane compared to carriers with A2 Alleles [38], [39]. There are many different mechanisms underlying the physiological and biological pathways of physical exercise and physical inactivity, and these are related to our obtaining health benefits [40]-[42]. It has been determined that exercise and allele frequencies are protective effects of depression genotyping in athletes. Genotyping studies in sport and regular physical exercise indicate that there is a protective aspect of the disease [43]. Most exercise epidemiology research suggests that different models and theories that compare with the psychosocial and environmental factors and physical inactivity phenotypes of different types of exercise are aware of the confusion of its variations [44]. Therefore, as shown in our study, we are thinking that DRD2 research in sports should open the way for knowledge of physical activity on many other genetic and environmental factors. For instance, Peripheral DA release is increased after exercise in highly effective anaerobic sprinter athlete. In addition to enhancing the activity of the nervous system which also affects the physiological mechanisms in the DA, it is also effective in stress response and motor control, and in general, the levels of the brain are increasing in the CNS due to endurance exercise. It has been reported that low membrane activity of the A1 Allele of D2 receptor plays a role in drug addiction [45]-[47].

In our study, RT-PCR was applied as a result of isolation process of the swap samples taken from the endurance and sprinter athletes and an image of the results was obtained. According to the results, 20 (15%) were AG (A1 / A2) and 17 (85%) were GG (A2 / A2) Genotypes and Allelic frequency distributions, A Allele 3 (7.5%) and G Allele 37 (92.5%), respectively. G Allele (A2) is accepted to be the wild type,

whereas A Allele (A1) is accepted as the polymorphic allele. Addiction or having tendency to addiction may be effective in athletic performance. In our cohort, none of the athletes carried the A1 Allele, which is related to addiction, when compared to A2 Allele. These results were in agreement with our results, in the terms of A2 Allele superiority.

DRD2 A1 Allele was found to be associated with addiction, and we hypothesized the same allele to be associated with sports addiction and by this way it is related with athletic performance. In our study, the frequency of A1 Allele was found to be lower than A1 Allele. Although we expected A1A1 homozygotes genotype founded, low sample size may be the reason for our results. Today, the results of the studies show that A1A2 Genotype are the highest number in individual.

There are not enough literature including rs1800497 polymorphism and athletes before body builders and volleyball players. In their cohort, A1A1, A1A2 and A2A2 Genotypes in bodybuilders were founded to be as 2 (13%), 1 (7%) and 12 (80%), respectively [48]. All the volleyball players had A2A2 Genotypes in their cohort. This study is in agreement with our, indicating the overrepresented of A1A2 and A2A2 Genotypes, and A2 Allele.

A comparison of the athletes from different sports to a control group can be important from the aspect of researchers being able to draw better defined conclusions. The type of genetic background can be important for being successful athlete to be able to have same performance at a high level and, but may not be that essential in every sport. Genotyping is related to SNP in successful athletes genome is important for sport medicine to find out the optimal alleles of the related genes. One of the restrictions of the present study is the small sample size. According to results for our writing, we are planning to replicate the study in different athletes. We could not find another study to compare our results; this is the second limitation of our discussion. We hope this first experiment will lead further studies in the terms of psychological and genetic factors.

## REFERENCES

- [1] Bray M. S., Hagberg J. M., Perusse L. et al. *The human gene map for performance and health-related fitness phenotypes*. Med Sci Sports Exercise, 2009, pp. 35–73.
- [2] Bouchard C, *Genomic predictors of trainability*. Exp Physiol, 2012, pp. 347– 352.
- [3] Wolfarth, B. Rankinen, T. Hagberg, J. M., Loos, R. J., Pérusse, L. Roth, S. M., Sarzynski, M. A., Bouchard, C. *Advances in exercise, fitness, and performance genomics in 2013*. Med Sci Sports Exercise. 2014, pp. 46 (5): 851- 9.
- [4] Tucker R. Collins, M. *What makes champions? A review of the relative contribution of genes and training to sporting success*. Br J Sports Med. 2012, pp. 46:555–561.
- [5] Calvo M, Rodas G, Vallejo M, et al. *Heritability of explosive power and anaerobic capacity in humans*. Eur J Appl Physiol. 2002, pp. 86(3): 218– 25.
- [6] Dahlström, A. Fuxe, K. *Localization of monoamines in the lower brain system*. Experientia.. 1964, 20(7): 398-9.
- [7] Stahl, S. M. *Psychosis and schizophrenia*. *Stahl's Essential Psychopharmacology*. Neuroscientific Basic and Practical Applications. 2013, Stahl S. M. with illustrations by Nancy Muntner. Cambridge University Press
- [8] Hornykiewicz, O. *The action of dopamine on the arterial pressure of the guinea pig*. Br J Pharmacol. 1958, pp. 13: 91- 94.

- [9] Foley, T. Fleshner, E. M. *Neuroplasticity of dopamine circuits after exercise: 498 implications for central fatigue*. 2008, pp. Neuromolecular Med. 10: 67-80.
- [10] Greco, B., Melis, M. Tonini, R. *Interplay between synaptic endocannabinoid signaling and metaplasticity in neuronal circuit function and dysfunction*. The European Journal of Neuroscience. 2014, pp. 39: 1189–1201.
- [11] Kent C. Berridge *Is Addiction a Brain Disease?* Neuroethics. 2016, pp. 10(1): 29-33.
- [12] Thompson, J. Thomas, N. Singleton, A. Piggott, M. L., Ioyd, S. Perry, E. K., Morris, C. M., Perry, R. H., Ferrier, I. N., Court, J. A. *D2 dopamine receptor gene (DRD2) Taq1 A polymorphism reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele*. Pharmacogenetics. 1997, pp. 7: 479±84.
- [13] Rabelo, P. C., Almeida, T. F., Guimaraes, J. B., Barcellos, L. A., Cordeiro L. M., Moraes, M. M., Coimbra, C. C., Szawka, R. E., Soares, D. D. *Intrinsic exercise capacity is related to differential monoaminergic activity in the rat forebrain*. Brain Res Bull. 2015, pp. 112: 7-13.
- [14] Romain, M. Meirleir, K. D. *Exercise and Brain Neurotransmission*. Sports Medicine. 1995, pp. 20(3): 160–188.
- [15] Baik, J. *Dopamine Signaling in reward-related behaviours* Front Neural Circuits. 2013, pp. 7: 152.
- [16] Terry, M. Elrath, Y. M., O'Malley, P. M. *Substance use and exercise participation among young adults: parallel trajectories in a national cohort-sequential study*. Addiction. 2011, pp. 106(10): 1855–1865.
- [17] Volkow, N. D., Wang, G. J., Newcorn, J. Fowler, J. S., Telang, F. Solanto, M. V., Logan, J. Wong, C. Ma, Y. Swanson, J. M., Schulz, K. Pradhan, K. *Brain dopamine transporter levels in treatment and drug naive adults with ADHD*. Neuroimage 2007, pp. 34: 1182–1190.
- [18] Vuckovic, M. G., Li, Q. Fisher, B. Nacca, A. Leahy, R. M., Walsh, J. P. *Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: in vivo imaging with ((1)(8)F)allypride*. Mov Disord. 2010, pp. 25: 2777–2784.
- [19] Carek, P. J., Laibstain, S. E. *Exercise for the treatment of depression and anxiety*. The International Journal of Psychiatry in Medicine. 2011, pp. 41(1): 15–28.
- [20] Haslacher, H. Michlmayr, M. Batmyagmar, D. Perkmann, T. Ponocny-Seliger, E. Scheichenberger, V. Scherzer, T. M., Nistler, S. Pilger, A. Dal-Bianco, P. Lehrner, J. Pezawas, L. Wagner, O. F., Winker, R. *rs6295 (C)-Allele Protects Against Depressive Mood in Elderly Endurance Athletes*. J Sport Exerc Psychol. 2015, pp. 37(6): 637-45.
- [21] Noble, E. P., Özkarağöz, T. Z., Ritchie, T. Zhang, L. X., Belin, R. T., Sparkes, R. S. *D2 and D4 Dopamine Receptor Polymorphisms and Personality*. American Journal of Medical Genetics (Neuropsychiatric Genetics). 1998, pp. 81: 257- 267.
- [22] Ford, C. P., Gantz, S. C., Phillips, P. E., Williams, J. T. *Control of extracellular dopamine at dendrite and axon terminals*. J. Neurosci.: Off. J. Soc. Neuroscience. 2010, pp. 30, 6975–6983.
- [23] Savitz, J. Hodgkinson, C. A., Martin-Soelch, C. Shen, P. H., Szczepanik, J., Nugent, A.C., Herscovitch, P., Grace, A. A., Goldman, D. Drevets, W. C. *DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder*. Int. J. Neuropsychopharmacol./Off. Sci. J. Coll. Int. Neuropsychopharmacol. (CINP). 2013, pp. 1–7.
- [24] Malo M. L., Brive, K. Luthman, Svensson P. *Selective pharmacophore models of dopamine D1 and D2 full agonists based on extended pharmacophore features*, ChemMedChem. 2010, pp. 5: 232-246.
- [25] Cooper, J. R., Bloom, F. E., Roth, R. H. *The Biochemical Basis of Neuropharmacology*. 2003, 8. Ed. Oxford University Press, New York, USA.
- [26] Balthazar, C. H., Leite, L. H., Rodrigues, A.G., Coimbra C.C. *Performance-enhancing and thermoregulatory effects of intracerebroventricular dopamine in running rats*. Pharmacol Biochem Behav. 2009, pp. 93: 465.
- [27] Gerald, M. C. *Effects of (+)-amphetamine on the treadmill endurance performance of rats*. Neuropharmacology. 1978, pp. 17:703.
- [28] Sedvall, G. Farde L. *Chemical brain anatomy in schizophrenia*. Lancet. 1995, pp. 346: 743- 749.
- [29] Meador-Woodruff, J. H., Damask, S. P., Wang, J. Haroutunian, V. Davis, K. L. Watson, S. J. *Dopamine receptor mRNA expression in human striatum and neocortex*. Neuropsychopharmacology. 1996, 15(1): 17-29.
- [30] Lahti, R. A., Roberts, R. C., Cochrane, E. V., Primus, R. J., Gallager, D. W., Conley, R. R., Tamminga, C. A. *Direct determination of dopamine D4 receptors in normal and schizophrenic postmortem brain tissue: a (3H)NGD-94-1 study*. Molecular Psychiatry Stockton Press. 1998, 3: 528-533.
- [31] Bunzow, J. R., Van, T. H., Grandy, H. M., D. K. *Cloning and expression of a rat D2 dopamine receptor cDNA*. Nature 1988, pp. 336: 783– 787.
- [32] Arinami, T., Itokawa, M., Aoki, J., Shibuya, H., Ookubo, Y., Iwawaki, A., Ota, K. Shimizu, H. Hamaguchi, H., Toru, M. *Further association study on dopamine D2 receptor S311C in schizophrenia and affective disorders*. Am. J. Med. Genet. 1996, pp. 67: 133-138.
- [33] Hirschfeld, R. M. *History and evolution of the monoamine hypothesis of depression*. The Journal of Clinical Psychiatry. 2000, pp. 61 (6): 4- 6.
- [34] Kishi, T., Okochi, T., Tsunoka, T., Okumura, T., Kitajima, T., Kawashima, K. Iwata, N. *Serotonin 1A receptor gene, schizophrenia and bipolar disorder: An association study and meta-analysis*. Psychiatry Research. 2011, pp. 185(1-2): 20– 26.
- [35] Carpenter, L. Angela, M. Wong, Zhaoping, L. Ernest, P. Noble, D. Heber *Association of Dopamine D2 Receptor and Leptin Receptor Genes with Clinically Severe Obesity* Obesity (Silver Spring). 2013, pp. 21(9): 467-73.
- [36] Gelernter, J. Yu, Y. Weiss, R. *Haplotype spanning TTC12 and ANKK1, flanked by the DRD2 and NCAM1 loci, is strongly associated to nicotine dependence in two distinct American populations*. Hum Mol Genet. 2006, pp. 15:3498– 3507.
- [37] Munafo, M. R., Matheson, I. J., Flint, J. *Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case-control studies and evidence of publication bias*. Mol Psychiatry. 2007, pp. 12:454– 461
- [38] Ariza, M., Garolera, M., Jurado, M. A., Garcia-Garcia, I., Hernan, I., Sanchez-Garre, C., Vernet-Vernet, M., Sender-Palacios, M. J., Marques-Iturria, I., Pueyo, R. Segura, B., Narberhaus, A. *Dopamine Genes (DRD2/ANKK1-Taq1A and DRD4-7R) and Executive Function: Their Interaction with Obesity*. Plos One. 2012, pp. 7(7): 41482
- [39] Thompson, J. Thomas, N. Singleton, A. Piggott, M. L., Ioyd, S. Perry, E. K., Morris, C. M., Perry, R. H., Ferrier, I. N., Court, J. A. *D2 dopamine receptor gene (DRD2) Taq1 A polymorphism reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele*. Pharmacogenetics. 1997, pp. 7: 479±84.
- [40] Noble, E. P., Özkarağöz, T. Z., Ritchie, T. Zhang, L. X., Belin, R. T., Sparkes, R. S. *D2 and D4 Dopamine Receptor Polymorphisms and Personality*. American Journal of Medical Genetics (Neuropsychiatric Genetics). 1998, pp. 81: 257- 267.
- [41] Hamilton, M. T., Hamilton, D. G., Zderic, T. W. (2007) *“Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease*. Diabetes. 2007, pp. 56: 2655–2667.
- [42] Vilhena S., D. M., Katzarzyk, P. T., Seabra, A. F., Maia, J. A. *Genetics of physical activity and physical inactivity in humans*. Behav Genetic. 2012, pp. 42:559-78.
- [43] Haslacher, H. Michlmayr, M. Batmyagmar, D. Perkmann, T. Ponocny-Seliger, E. Scheichenberger, V. Scherzer, T. M., Nistler, S. Pilger, A. Dal-Bianco, P. Lehrner, J. Pezawas, L. Wagner, O. F., Winker, R. *rs6295 (C)-Allele Protects Against Depressive Mood in Elderly Endurance Athletes*. J Sport Exerc Psychol. 2015, pp. 37(6): 637-45
- [44] Dishman, R. K., Sallis, J. F., Orenstein, D. R. *The determinants of physical activity and exercise*. Public Health Rep. 1984, pp. 100:158–171.
- [45] Charlotte, H., Bartels, M., Groen-Blokhuis, M. M., Dolan, C. V., de Moor, M. H. M., Abdellaoui, A., Beijsterveldt, V., C. M., Ehli, E. A., Hottenga, J. J., Willemsen, G., Xiao, X., Scheet, P., Davies, G. E., Boomsma, D. I., Hudziak, J. J., De Geus, J. C. *The Dopaminergic Reward System and Leisure Time Exercise Behavior: A Candidate Allele Study*. BioMed Research International Volume, Article ID 591717, 2014, pp. 9.
- [46] Hamajima, N. Ito, H. Matsuo, K. Saito, T. Tajima, K. Ando, M. *Association between smoking habits and dopamine receptor D2 taq1A A2 allele in Japanese males: a confirmatory study*. J Epidemiol. 2002, pp. 12:297–304.
- [47] Winter, B. Breitenstein, C. Mooren, F. C., Voelker, K. Fobker, M. Lechtermann, A. *High impact running improves learning*. Neurobiol Learn Mem. 2007, pp. 87: 597-609.
- [48] İpek Yüksel, Sezgin Kapıcı, Canan Sercan, Hamza Kulaksız, Tolga Polat, Güllü Turan, Korkut Ulucan. *Addiction related DRD2 rs1800497 polymorphism distribution in volleyball players and bodybuilders*. The Journal of Neurobehavioral Sciences, 4(3), 122-125, 2017.